Holen Sie sich die Stockscreener-App
21.44
2.83%
-0.62
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Brokers Set Expectations for Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given New $44.00 Price Target at Royal Bank of Canada - MarketBeat
RBC raises Viridian Therapeutics shares price target, maintains Outperform rating - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $31.00 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 4.8% on Analyst Upgrade - MarketBeat
Trend Tracker for (VRDN) - Stock Traders Daily
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - BioSpace
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - StockTitan
Viridian Therapeutics Says Selling 10.7 Mln Shares Of Common Stock At $18.75 Per Share - XM
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire
Viridian Therapeutics launches $150 million public offering - Investing.com India
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Nasdaq
Needham & Company LLC Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com Canada
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Zacks Investment Research
Needham raises Viridian stock price target, maintains Buy rating By Investing.com - Investing.com Canada
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load? - Simply Wall St
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Yahoo Finance
Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - BioSpace
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com Canada
Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - Scrip
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from HC Wainwright - MarketBeat
Items Tagged with 'veligrotug' - BioWorld Online
Why are Viridian Therapeutics shares on the rise on Tuesday? - Mugglehead
Viridian Therapeutics launches $150 million public offering - Investing.com
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way (NASDAQ:VRDN) - Seeking Alpha
Viridian Thrives on phase III with veligrotug in thyroid eye - BioWorld Online
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com South Africa
How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition - Investor's Business Daily
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics - Investing.com India
Viridian Therapeutics launches $150 million public offering By Investing.com - Investing.com UK
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know - Benzinga
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - StockTitan
Viridian stock jumps on data for lead asset (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com
Viridian Therapeutics price target raised to $40 from $33 at Stifel - TipRanks
Viridian Therapeutics stock gains confidence with improved efficacy and safety data - Investing.com UK
BTIG Research Boosts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $56.00 - MarketBeat
Viridian Therapeutics (VRDN) Shares Cross Above 200 DMA - Nasdaq
Biotech Stock Scores Big Win, Squeezes Shorts - Schaeffers Research
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival - MSN
Viridian's drug cuts thyroid eye disease symptoms in late-stage study - Reuters
Viridian Therapeutics’ eye disorder treatment meets main goal in late-stage study - WKZO
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival - Inkl
Financial Snapshot: Analyzing Viridian Therapeutics Inc (VRDN)’s Key Ratio Metrics - The Dwinnex
Viridian Therapeutics Inc (VRDN)’s stock performance: a year in review - US Post News
Why Is Viridian Therapeutics Stock Trading Higher On Tuesday?Viridian Therapeutics (NASDAQ:VRDN) - Benzinga
VRDNViridian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Viridian Therapeutics Shares Rise on Positive Results of Veligrotug in Thyroid Eye Disease Trial - MarketWatch
Viridian Therapeutics rises as eye disorder treatment meets main goal in late-stage study - XM
Viridian Therapeutics’ Veligrotug Triumphs in THRIVE Trial - TipRanks
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - StockTitan
Viridian Therapeutics launches $150 million public offering By Investing.com - Investing.com Canada
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 - StockTitan
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Candriam S.C.A. - MarketBeat
Viridian Therapeutics Inc (VRDN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Market Momentum: Viridian Therapeutics Inc (VRDN) Registers a -9.23 Decrease, Closing at 13.47 - The Dwinnex
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 6.3% - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 2.9% - MarketBeat
You might want to take a look at Viridian Therapeutics Inc (VRDN) now - SETE News
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $31.20 Consensus Price Target from Brokerages - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from Needham & Company LLC - Defense World
Viridian Therapeutics shares hold Buy rating from Needham, focus on upcoming Phase 3 trial outcomes - Investing.com Australia
Viridian Therapeutics (NASDAQ:VRDN) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
Viridian Therapeutics: Key Inflection Points Ahead (NASDAQ:VRDN) - Seeking Alpha
1.19%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):